Puma Biotechnology Q2 net income $2.1M, down from $9.4M YoY; revenue flat at $51.6M

PUMA BIOTECHNOLOGY, INC.

2023-Q2 EPS reported $0.07 revenue$107,343,000

GAAP net income $2.1M ($0.05/diluted share) vs $9.4M ($0.21) Q2 2022; non-GAAP adj net income $4.6M ($0.10).
Product revenue from NERLYNX $51.6M, slightly up from $51.3M YoY; royalty revenue fell to $3.0M from $8.2M.
Net cash from operations positive $3.3M vs -$13.9M Q2 2022; cash & securities $74.4M at June 30.
FY 2023 guidance: product revenue $205-210M, net income $20-24M; Q3 product revenue guided $51-53M.
Pipeline milestones: Phase II alisertib in small cell lung cancer H2 2023; FDA meeting Q4 for HR+ HER2- breast cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PUMA BIOTECHNOLOGY, INC. reported the second quarter ended June 30, 2023 results: revenue $51.6 million, net income $2.1 million, EPS $0.05 per basic and diluted share.

Period: the second quarter ended June 30, 2023
Revenue: $51.6 million
Net income: $2.1 million
EPS: $0.05 per basic and diluted share
Result: reported results

Exact text from the filing

Product revenue, net in the second quarter of 2023 was $51.6 million, an increase from $51.3 million reported for the second quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PUMA BIOTECHNOLOGY, INC. reported the first six months of 2023 results: revenue $98.3 million, net income $3.5 million, EPS $0.08 per basic share and $0.07 per diluted share.

Period: the first six months of 2023
Revenue: $98.3 million
Net income: $3.5 million
EPS: $0.08 per basic share and $0.07 per diluted share
Result: reported results

Exact text from the filing

Product revenue, net in the first six months of 2023 was $98.3 million, compared to $92.0 million in the first six months of 2022.

View on SEC.gov

Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-021937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.